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Abstract: Introduction: Intravenous antibiotic therapy (IVAT) for CF acute pulmonary exacerbations (APE) can be 
delivered in hospital or in the community. This study aimed to compare physical activity in CF patients receiving hospital 
and community-delivered IVAT, as well as other health outcomes. 
Materials and Methods: This was a non-randomised parallel group prospective observational study. Hospitalised and 
community-treated CF adults receiving IVAT for APE were asked to wear ActiGraph® activity monitors, complete the 
habitual activity estimation scale (HAES), food diary, modified shuttle test (MST) and CFQ-R at the start and end of 
therapy. Nutritional and clinical outcomes were also compared between the cohorts. The primary outcomes was physical 
activity measured by the ActiGraph® activity monitors at the beginning and end of treatment in both cohorts. 
Results: Physical activity (measured and self-reported) was no different between the cohorts, with both hospitalised and 
community-treated subjects being generally sedentary. Body weight increased significantly in the hospitalised cohort, 
whereas no difference was seen in the community-treated cohort. FEV1 % predicted and FVC % predicted increased in 
community-treated subjects, whereas only FVC % predicted increased in hospitalised subjects. CFQ-R respiratory domain 
increased to a greater extent in community-treated subjects. 
Conclusion: CF adults receiving IVAT for APE, both in hospital and in the community, are generally sedentary and we 
found no difference in physical activity between the two groups. These findings suggests the need to further promote 
physical activity in suitable patients during APE where considered appropriate. 
Keywords: Cystic fibrosis, habitual, intravenous antibiotics, nutrition, physical activity. 
1. INTRODUCTION 
 People with cystic fibrosis (CF) experiencing acute 
pulmonary exacerbations (APE) commonly require 
intravenous antibiotic therapy (IVAT) and this may be 
delivered in hospital or in the community. Previous research 
has produced conflicting evidence when comparing the 
relative benefits of hospital-based and community-based 
IVAT in CF. Several studies have demonstrated benefits for 
hospitalised patients [1-5], but others have found equivalent  
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outcomes for hospital and community treatment [6-10]. 
Potential reasons that hospitalisation may be more beneficial 
include closer contact with the CF multi-disciplinary team, 
improved adherence, the availability of additional 
intravenous treatments such as aminophylline and the ability 
to escalate care if clinical status deteriorates. However, there 
are potential drawbacks of hospital admission, including 
potential increased cross-infection risks [11] and disrupted 
sleep, social and family life [12]. There are also financial 
implications associated with hospitalisation, with increased 
costs for the healthcare provider, as well as potential loss of 
earnings and costs of travel and parking for patients and 
carers [12,13]. 
 There is a long-established consensus that physical 
activity is beneficial for CF patients [14-16]. Exercise has 
been demonstrated to improve ease of expectoration [17], 
exercise capacity [18], quality of life (QoL) [18], and slow 
lung function decline [19] in the stable state. However, there 
is a lack of research examining the effects of exercise during 
APE. A recent study, comparing physical activity of patients 
16    The Open Respiratory Medicine Journal, 2015, Volume 9 Khiroya et al. 
during hospital admission and one month after hospital 
discharge, demonstrated reduced physical activity during 
hospital admission compared to the follow-up period [20]. 
Bed-rest during APE has previously been suggested to be of 
benefit [21] and it is likely that in certain subgroups of 
patients this is indeed the case. However, there is mounting 
evidence that where feasible, maintaining physical activity 
during APE is beneficial. Indeed, Selvadurai et al. [22] 
found that when standard inpatient care was supplemented 
with aerobic exercise during APE, children with CF had 
significantly greater peak aerobic capacity, activity levels 
and QoL following discharge. 
 In a prospective study, CF patients randomly allocated to 
receive IVAT in hospital experienced less fatigue than those 
treated in the community [9]. Additionally ‘general activity 
was higher in the home group as patients performed routine 
household and social duties’, reflecting increased activity in 
community treated patients. However, physical activity was 
not directly measured in this study and we are not aware of 
any previous studies comparing the physical activity of CF 
patients receiving IVAT in hospital and in the community. 
The purpose of the current study was therefore to compare 
the physical activity of CF adults receiving IVAT in these 
two settings, as well as health-related QoL, spirometric and 
nutritional outcomes. The primary outcome was physical 
activity as measured by the Actigraph® GT3X activity 
monitor and we hypothesised that community-treated 
patients would perform significantly more physical activity 
than their hospitalised counterparts. 
2. MATERIALS AND METHODS 
2.1. Subjects and Assessments 
 West Midlands (Solihull) Research Ethics Committee 
provided local ethical approval for this non-randomised 
parallel group prospective observational study (Reference 
no. 12/WM/0028). Subjects were recruited at West Midlands 
Adult CF Centre, Birmingham, UK, with the centre caring 
for approximately 370 CF adults during the study period. 
Inclusion criteria were: written informed consent, confirmed 
diagnosis of CF, aged 16 years and over, chronic infection 
with Pseudomonas aeruginosa, requirement for IVAT for 
APE as assessed by the direct care team at screening and a 
plan for patients to receive the entire course of IVAT either 
in hospital or in the community. Exclusion criteria were: 
pregnancy, breast feeding, previous lung transplantation, 
resting transcutaneous oxygen saturations <94%, a plan to 
change dosage of corticosteroids during the course of 
antibiotics and if patients were deemed by the treating 
physician to be too unwell for home IVAT. Location of 
IVAT was based on a combination of patient and clinician 
preference and was decided prior to patients being recruited. 
 Subjects receiving community treatment had baseline 
assessments performed in the clinic area immediately 
following the decision to start IVAT and follow-up 
assessments were performed when patients re-attended 
immediately after completing IVAT. Hospitalised subjects 
had baseline assessments performed within three days of 
hospital admission and follow-up assessments performed 
within the three days prior to completing IVAT. Baseline 
characteristics were recorded, including: age, gender, lung 
function (actual and predicted values of FEV1 and FVC), 
weight, body mass index (BMI), CF-related diabetes status, 
CF liver disease status, average daily oral corticosteroid dose 
(if any) and sputum bacteria other than Pseudomonas 
aeruginosa. At the follow-up visit, lung function, weight, 
BMI, oral corticosteroid dose, duration and details of IVAT 
were documented. At baseline and follow–up visits, subjects 
were asked to complete the Cystic Fibrosis Questionnaire-
Revised (CFQ-R), the Habitual Activity Estimation Scale 
(HAES) and the Modified Shuttle Test (MST). The CFQ-R 
is a health-related QoL questionnaire validated for use in CF 
adults [23]. Only the respiratory and digestion domains were 
extracted, since these domains were felt to be most relevant. 
The HAES is a patient-reported measure of habitual activity 
and the MST is an externally paced incremental exercise test, 
with both being validated in CF [24,25]. Heart rate, oxygen 
saturations and perceived breathlessness on the modified 
Borg scale were recorded at the start and end of the MST. 
The number of 10-metre shuttles completed was also 
recorded. 
 Subjects were instructed to wear an Actigraph® GT3X 
activity monitor, a tri-axial accelerometer, for three 
consecutive days during the first week and three consecutive 
days during the second week of IVAT. The accelerometer 
was to be worn around the subjects’ waist during waking 
hours, except whilst bathing or other direct contact with 
water. This accelerometer was chosen because a previous 
version has been validated for use in CF [26]. Analysis of 
Actigraph® GT3X data from each subject was performed 
using ActiLife 5 software (ActiGraph® R&D and Software 
Department, Pensacola, FL), providing six default intensity 
levels, simplified to four cut points (see Table 1). 
Table 1. Cut off points used to categorise activity monitor-
measured physical activity levels. 
 
Default Cut Points Range of Counts Modified Cut Points 
Sedentary 0-100 Sedentary 
Lifestyle 101-759 Light 
Light 760-1952 Light 
Moderate 1953-5742 Moderate 
Vigorous 5725-9498 Vigorous 
Very vigorous >9598 Vigorous 
 
 Subjects did not wear the accelerometer while 
performing the MST. Subjects were also asked to complete a 
detailed food diary for three consecutive days during the first 
week and three consecutive days during the second week of 
IVAT, with food intake data being analysed using Dietplan6 
software (Forestfield Software, UK). Estimated energy 
intake (from the food diary) minus estimated energy 
expenditure (from the accelerometer), allowed calculation of 
estimated energy balance. 
 Hospitalised subjects recruited to the study were not 
treated any differently to other patients admitted during the 
same period but not recruited to the study. They were offered 
regular physiotherapy input and encouraged to use our 
inpatient gym, based in the CF centre, as usual. Nutritional 
input was also as standard for other CF inpatients on our 
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ward, with regular dietetic input, three daily meals, 
additional high-calorie snacks and nutritional supplement 
drinks. Subjects receiving IVAT in the community were not 
offered any additional physiotherapy or dietetic input beyond 
that which was clinically indicated. 
2.2. Statistical Analysis 
 All statistical testing was two-sided and performed at the 
5% significance level using Statistical Package for Social 
Sciences (SPSS) version 16 software. The Kolmogorov-
Smirnov test was used to determine data normality. The 
majority of results were found to be non-normally distributed 
therefore descriptive statistics are expressed as median 
values and Mann Whitney U tests and Spearman’s rho 
correlations were performed. Descriptive statistics that were 
normally distributed are expressed as mean values and in the 
cases of normal distribution, t-tests and Pearson’s 
correlations were used. 
3. RESULTS 
 Forty-five subjects were recruited between January and 
October 2012, with 22 subjects in the hospital-treated group 
and 23 subjects in the community-treated groups. Three 
hospitalised subjects were recruited to the study, but were 
subsequently withdrawn from the analysis because they were 
discharged from hospital during IVAT. Therefore data was 
analyzed for 19 hospital-treated and 23 community-treated 
patients. Baseline data (Table 2) shows that subjects within 
the hospitalised and community cohorts were generally 
comparable, with the exception of FVC% predicted, which 
was significantly higher in the community cohort. Table 2 
also demonstrates how many subjects participated in each 
aspect of data collection. 
 All patients received combinations of two or three anti-
pseudomonal IV antibiotics. Community-treated patients all 
received two antibiotics from a combination of tobramycin, 
meropenem, ceftazidime, colistin, piperacillin/tazobactam or 
aztreonam. Two hospitalised patients were on three 
antibiotics, and the rest received two antibiotics from a 
combination of tobramycin, meropenem, ceftazidime, 
colistin, piperacillin/tazobactam, aztreonam, fosfomycin, 
tigecycline or flucloxacillin. Thirteen subjects were taking 
prednisone: the median daily dose was not significantly 
different in community-treated and hospitalised patients (13 
mg vs 17.5 mg). 
 Ten hospitalised and 17 community subjects wore the 
accelerometer during the first and second weeks of IVAT, 
with a further 7 hospitalised and 3 community subjects only 
wearing the accelerometer for the first week. Accelerometer 
data demonstrated that subjects in both hospitalised and 
community cohorts spent the majority of their time in the 
sedentary activity level during the first week 
(hospital=87.47%, community=83.95%) with the median 
percentage of activity falling as the intensity of activity 
increases (Fig. 1). This pattern is mimicked in the data from 
the second week, with the median percentage of activity 
falling as the intensity increases (hospital=76.75%, 
community=85.48%) (Fig. 1). During the first and second 
week there was no statistically significant difference between 
the groups for any of the activity levels. Overall, males did 
significantly more vigorous exercise than females (p=0.024). 
 Nine subjects in the hospital group and 18 subjects in the 
community group completed the HAES questionnaire at the 
beginning and end of IVAT. Both cohorts reported spending 
their time predominantly in the somewhat inactive (SI) and 
somewhat active (SA) activity levels (Fig. 2). As with the 
results from the accelerometer, there was no statistically 
significant difference between the groups. For the questionnaire 
Table 2. Baseline characteristics of study participants. 
 
Characteristic Community n Hospital n 
AGE, years (median) 33.5  23 27.4 19 
GENDER 
Male 
Female 
 
 
 
6 
17 
 
 
 
9 
10 
CO-MORBIDITIES 
CF-related diabetes 
CF-related liver disease 
 
 
 
14 
2 
 
 
 
7 
4 
EXERCISE CAPACITY 
Number of shuttles on MST (mean)  
 
54 
 
18 
 
58 
 
18 
NUTRITION 
Weight, kg (mean) 
BMI, kg/m2 (mean) 
 
58.5 
22.3 
 
23 
 
 
57.6 
21.5 
 
19 
 
PFTs 
FEV1 % predicted (mean) 
FVC % predicted (mean) 
 
50.5 
77.7 
 
22 
 
 
48.3 
66.6 
 
19 
 
QUALITY OF LIFE 
CFQ-R Respiratory domain (mean) 
CFQ-R Gastrointestinal domain (median) 
 
41 
89 
 
22 
 
 
56 
83 
 
16 
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completed at the end of IVAT, males spent significantly more 
time in the SI activity level than females (p=0.023). 
Fig. (1). Activity monitor-measured physical activity levels in 
community and hospital-treated patients. 
Fig. (2). HAES-measured physical activity levels in community and 
hospital-treated patients. 
 Six hospitalised subjects and 11 community-treated 
subjects completed the MST at the start and end of IVAT, 
with number of shuttles completed significantly increasing in 
both cohorts. There was no statistically significant difference 
between the hospitalised cohort (68 shuttles pre-IVAT vs 
84.3 shuttles post-IVAT) and the community cohort (57.4 
shuttles pre-IVAT vs 67.5 shuttles post-IVAT). There was no 
correlation between change in MST and lung function. There 
was also no correlation between change in MST and 
percentage of sedentary activity on the accelerometer. Males 
performed more shuttles than females overall (p=0.022) 
when the MST results from the beginning and end of IVAT 
were combined. 
 There were no significant differences in estimated energy 
intake, expenditure or balance between hospitalised and 
community-treated cohorts, either in the first or second week 
of IVAT (Table 3). 
 During the first week of IVAT, males had greater energy 
intake than females (p=0.034), however overall there was no 
difference between the genders. Body weight of hospitalised 
subjects increased significantly during IVAT, but no such 
difference was seen in community-treated subjects (Table 4). 
 Fig. (3) demonstrates the correlation between weight 
change and energy balance in both cohorts combined (RP 
0.68, p=0.0005). 
 
Fig. (3). Correlation between estimated energy balance and weight 
change in all study participants combined. 
 FEV1% predicted and FVC% predicted increased 
significantly in community-treated subjects during IVAT 
(Table 4). Although FVC% predicted increased significantly 
in hospitalised subjects, this cohort showed only a non-
significant increase in FEV1% predicted comparing values 
before and after IVAT (Table 4). 
 Nine hospitalised subjects and 13 community-treated 
subjects completed the CFQ-R at the beginning and end of 
IVAT. The digestion domain did not change significantly 
over the course of IVAT (p=0.727), with no significant 
difference between hospitalised and community-treated 
subjects. The respiratory domain did improve significantly 
over the course of IVAT (p=0.004), with a significantly 
greater improvement for community-treated subjects 
(p=0.02). Questions that showed particular discrepancies 
between hospitalised and community-treated subjects 
included “have you had trouble breathing?” and “have you 
woken up during the night because you were coughing?” 
There was no significant correlation between the change in 
CFQ-R respiratory domain scores and change in FEV1 (Rs 
0.185, p=0.634). 
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4. DISCUSSION 
 This is the first study to compare physical activity in CF 
patients receiving IVAT in hospital and in the community, 
finding no significant difference in directly measured 
between the two cohorts. Self-reported physical activity, 
measured by the HAES, also showed no difference between 
the cohorts. Subjects in both cohorts spent the majority of 
their time sedentary during the treatment period, with no 
increase in activity comparing the beginning and end of 
IVAT. Body weight increased significantly in hospitalised 
subjects, whereas no significant increase was seen in 
community treated subjects. 
 CF patients receiving IVAT in the community were 
previously assumed to be more active than their hospitalised 
counterparts, since they are theoretically better able to 
continue with their routine daily activities [9]. However, this 
has not previously been directly measured and we have 
relied on patient testimony as to the perceived benefits of 
community-delivered treatment. We are aware from previous 
studies that patients often over-estimate their levels of 
physical activity and that is confirmed in the current study. 
Despite most participants self-reporting their activity levels 
as being ‘somewhat active’ or ‘somewhat inactive’, 
accelerometer data demonstrated that the vast majority were 
in fact sedentary. 
 In some ways the observed low levels of physical activity 
is unsurprising, since patients experiencing an APE are less 
likely to feel well enough to exercise and to take part in 
routine daily activities. The additional burden of IVAT, with 
most community-treated patients being required to draw up 
and administer their own antibiotics on four or five separate 
occasions every day, is likely to further limit the opportunity 
for physical activity. Hospitalised patients, in contrast, 
usually have IVAT prepared and administered by nursing 
staff, which potentially affords patients extra ‘free time’ in 
which to remain physically active. Patients admitted to our 
centre are encouraged to exercise on a daily basis and have 
exclusive access to a well-equipped gymnasium located 
within our inpatient ward. Since hospitalised subjects were 
encouraged to exercise and were free of the distractions of 
work and education, this may theoretically have allowed 
them to focus more on remaining active. 
 It has previously been demonstrated that hospitalised CF 
patients have better nutritional outcomes than community-
treated patients [3] and a potential explanation for this 
observation is reduced activity in hospitalised patients. The 
current study also demonstrates that hospitalised patients had 
better weight gain than community-treated patients, but this 
was not associated with differences in directly observed or 
self-reported physical activity levels. Another potential 
factor explaining the observed better nutritional outcomes in 
hospitalised patients is a more intensive focus on optimising 
dietary intake. Indeed, as is the case in the majority of CF 
centres, a dietician sees every patient admitted to our centre 
at regular intervals during their admission, ensuring that 
patients are offered specialist dietary advice. In addition, 
patients admitted to our centre are able to order specially 
Table 3. Estimated energy intake, expenditure and balance derived from analysis of food diary and activity monitor data. 
 
Variable Community n Hospital n p Value 
Energy intake (kcal) 
First 3 days 
Last 3 days 
 
2028 
2179 
 
21 
19 
 
2682 
2646 
 
16 
9 
 
0.132 
0.314 
Energy expenditure (kcal) 
First 3 days 
Last 3 days 
 
207 
221 
 
20 
17 
 
135 
160 
 
17 
10 
 
0.055 
0.114 
Energy balance 
First 3 days 
Last 3 days 
 
1882 
1953 
 
19 
17 
 
2606 
2660 
 
15 
8 
 
0.101 
0.160 
 
Table 4. Body weight and spirometry before and after IV antibiotic treatment in community and hospital-treated subjects. 
 
Variable n Before Treatment After Treatment p Value 
Weight (kg) 
Community 
Hospital 
 
18 
12 
 
58.8 
62.6 
 
58.6 
64.6 
 
0.348 
0.014 
Spirometry 
FEV1 % predicted 
Community 
Hospital 
 
 
18 
12 
 
 
46.9 
47.5 
 
 
50.7 
52.8 
 
 
0.037 
0.265 
FVC % predicted 
Community 
Hospital 
 
18 
12 
 
71.0 
64.9 
 
76.2 
76.0 
 
0.032 
0.012 
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prepared high-calorie meals and snacks in addition to the 
standard hospital food served to non-CF patients in other 
wards. However, we observed no significant difference in 
energy intake or energy balance when comparing 
hospitalised and community-treated subjects. Superior 
nutritional outcomes in hospitalised patients could also 
theoretically be due to more intensive antibiotic treatment or 
use of systemic corticosteroids, but again we saw no 
significant differences in the use of these treatments between 
the cohorts. Since changes in body weight often reflect 
changes in spirometry in people with CF, another potential 
reason for improved nutritional outcomes in hospitalised 
patients could be improved pulmonary function. Although 
absolute values of FEV1% predicted and FVC% predicted 
increased in both hospitalised and community-treated 
patients, the increase in FEV1% predicted did not increase 
significantly in hospitalised patients. This study therefore 
does not provide a clear explanation for the better nutritional 
outcomes observed in the hospitalised cohort. 
 Wells et al. [24] compared self-reported and directly 
measured physical activity in CF adolescents in the stable 
state, using the HAES questionnaire and a similar 
accelerometer to that used in the current study. They 
demonstrated a highly significant positive correlation 
between the results generated by these two methods 
(p<0.0001). The findings of the current study provide further 
evidence of the validity of the HAES questionnaire. As was 
reported by Wells et al., patients reported higher levels of 
activity than were directly recorded by the accelerometer. 
This discrepancy was more marked in the current study, 
which is likely due to the differences in clinical status, since 
we studied patients experiencing an APE and Wells et al. 
studied patients in the stable state. 
 Community-treated subjects in the current study had a 
significantly greater increase in the respiratory domain of the 
CFQ-R than the hospitalised subjects. We found this 
interesting since it was contrary to what would be expected 
from previous research suggesting that community-treated 
patients experience higher levels of fatigue due to being 
more dyspnoeic [9]. A potential explanation for our finding 
is that since community-treated subjects were in their normal 
home environment, they may have been comparing their 
respiratory symptoms to their baseline stable state. Hospital-
treated subjects were potentially more aware of their clinical 
status due to their hospital surroundings, which may have 
reduced expectations of their respiratory symptoms. 
 We acknowledge several limitations of the current study. 
Only 10 of the 19 hospitalised subjects wore the 
accelerometer during both the first and second week of 
IVAT. Although a further seven hospitalised patients wore 
the accelerometer solely during the first week, this limits the 
reliability our findings. The most frequent reason cited for 
failing to wear the monitor as per protocol was that patients 
simply forgot, although it is certainly feasible that the more 
unwell patients were more likely to fail to wear the monitor. 
Several community-treated patients also failed to complete 
the MST at the end of IVAT despite undertaking it at the 
start. This was usually due to a lack of time, or feeling too 
unwell. The latter could potentially bias the results if patients 
who showed the most clinical improvement tended to 
complete the test. In addition, since we excluded patients 
that were more significantly unwell, our findings are not 
applicable to all CF adults requiring IVAT. The inclusion 
criteria were used in an effort to make the baseline 
characteristics of both cohorts comparable, but they could 
have selected patients that were more active in the 
hospitalised cohort and this could explain the lack of 
difference in physical activity between the cohorts. 
CONCLUSION 
 In summary, this study demonstrates that hospitalised 
and community-treated CF adults receiving IVAT for APE 
are generally sedentary, with no significant difference in 
physical activity between the two groups. The relatively low 
intensity of physical activity in both hospitalised and 
community-treated patients suggests the need to further 
promote physical activity in suitable patients during APE 
where considered appropriate. Our findings demonstrate the 
need for further research examining physical activity levels 
in CF patients experiencing APE, as well as the potential 
benefits of exercise programmes for both hospitalised and 
community-treated patients. 
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